| Name | Title | Contact Details |
|---|---|---|
David Esposito |
President and Chief Executive Officer | Profile |
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.
Pear Therapeutics is a privately held prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious medical conditions and is the leader in FDA-authorized prescription digital therapeutics.
SciMed Technologies Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations.